Pigmentation of the Tongue, Nails, and Gingiva Following Adriamycin Therapy: A Literature Review and Clinical Insights Pigmentation related adriamycin therapy
Article Sidebar
Main Article Content
Abstract
Objective: Hyperpigmentation in the mucosa of the tongue and mouth may also occur with the administration of combination chemotherapy containing doxorubicin (Adriamycin). Chemotherapeutic agents may occasionally necessitate discontinuation, either temporarily or permanently, despite the fact that most of these side effects are purely cosmetic and resolve following treatment. The return of nail growth and coloration a few weeks or months after therapy cessation suggests the involvement of chemotherapeutic drugs. Following Adriamycin administration, pigmentation observed in the tongue, nails, and oral mucosa typically diminishes upon discontinuation of the medication without the need for additional treatment. However, careful monitoring is essential to ensure that no alternative explanations are overlooked.
Conclusion: To enhance awareness and facilitate the exchange of experiences regarding the management of this rare side effect, we present four cases of patients who developed nail, oral mucosa, and gingiva pigmentation following combination therapy with Adriamycin and cyclophosphamide in our clinic.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-03-17
Published 2024-03-28
References
Saraswat N, Sood A, Verma R, Kumar D, Kumar S. Nail changes induced by chemotherapeutic agents. Indian Journal of Dermatology. 2020;65(3):193.
Hinds G, Thomas VD. Malignancy and cancer treatment-related hair and nail changes. Dermatologic clinics. 2008;26(1):59-68.
Piraccini BM, Iorizzo M, Starace M, Tosti A. Drug-induced nail diseases. Dermatologic clinics. 2006;24(3):387-91.
Jones SE, Durie BG, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 1975;36(1):90-7.
Hong WS, Jeon JY, Kang SY, Jung YS, Kim JY, Ahn MS, et al. Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer. Journal of the Korean Surgical Society. 2013;85(1):7-14.
Blaya M, Saba N. Chemotherapy-induced hyperpigmentation of the tongue. N Engl J Med. 2011;365(10):e20.
Dasanu CA, Vaillant JG, Alexandrescu DT. Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatology Online Journal. 2006;12(6):10-.
Piraccini BM, Alessandrini A. Drug-related nail disease. Clinics in dermatology. 2013;31(5):618-26.
Gadisa DA, Assefa M, Wang S-H, Yimer G. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study. Journal of Oncology Pharmacy Practice. 2020;26(8):1912-20.
Palappallil DS, Nair BLR, Jayakumar K, Puvathalil RT. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian Journal of Cancer. 2011;48(1):68-73.
Yorulmaz A, Dogan M, Artuz F, Zengin N. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation. Cutaneous and Ocular Toxicology. 2017;36(2):135-9.
Willems M, Munte K, Vrolijk J, Den Hollander J, Böhm M, Kemmeren M, et al. Hyperpigmentation during interferon‐alpha therapy for chronic hepatitis C virus infection. British Journal of Dermatology. 2003;149(2):390-4.
Abbasi NR, Wang N. Doxorubicin-induced hyperpigmentation. Dermatology Online Journal. 2008;14(10):18.